secwatch.observer — SEC 8-K summary
======================================

Issuer:     Repare Therapeutics Inc. (—)
CIK:        0001808158
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-054486
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repare Therapeutics reports Q1 net income $13.2M; FDA agrees on RP2D for lunresertib+camonsertib combination
--------------------------------------------------------------------------------

- Net income of $13.2M ($0.30 diluted) vs loss of $34.9M a year ago; revenue $52.4M primarily from $40M Roche milestone.
- Cash, equivalents and marketables $237M, sufficient to fund operations at least into mid-2026.
- FDA agreed to RP2D for lunresertib 80mg BID + camonsertib 80mg QD; Grade 3 anemia reduced to 25% from 45%.
- Regained global rights to camonsertib from Roche; cumulative $182.6M received from Roche under collaboration.
- First patient dosed in Phase 1 LIONS trial of PLK4 inhibitor RP-1664; expecting pivotal trial start for lunresertib combo in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808158/000095017024054486/0000950170-24-054486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808158/000095017024054486/rptx-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-054486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer